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ABSTRACT
Objective: Periodontitis, a chronic inflammatory disease characterized by destruction of the periodontal ligament and alveolar bone is the sixth 
complication of diabetes mellitus. Periodontal treatment that reduces gingival inflammation aids in the control of hyperglycemia. Therefore, the 
present study was designed to determine the effect of treating chronic periodontitis with oral antibiotics azithromycin and metronidazole on the level 
of serum glycated hemoglobin in type-II diabetic patients.
Methods: This prospective observational study was carried out in the dental department of a tertiary care hospital for 9 months. Clinical and 
biochemistry reports of 90 patients were collected in designed case report forms. All statistical analyses were performed using IBM Statistical Package 
for Social Sciences 17 and Graph Pad Prism 7.0.
Results: Significant reduction in all the clinical and dental parameters was comparatively higher in patients who received azithromycin than in 
patients who received metronidazole and scaling and root planning alone.
Conclusion: Periodontal therapy with oral azithromycin can be employed as a supportive strategy for the management of diabetes mellitus. 
Henceforth, prevention and control of periodontal disease along with antibiotics must be considered an integral part of glycemic control. However, 
due to the lesser sample size in this study, further investigations are required to confirm the effect of periodontal therapy on systemic diseases.
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INTRODUCTION
Oral hygiene plays a critical role in whole-body health. There has been an 
emerging interest in the interrelationship between systemic conditions 
and oral health. Periodontal diseases are a group of inflammatory, 
microbial-induced infections involving the supporting tissues of the 
teeth and mainly caused by gram-negative, anaerobic bacteria [1,2]. The 
American Society of Diabetes defined periodontal disease as the sixth 
complication of diabetes in 1997 [3]. Pathogens which are commonly 
involved in causing periodontitis are Porphyromonas gingivalis, 
Prevotella intermedia, Tannarella forsythia and Aggregatibacter 
actinomycetmcomintans, which lead to soft and hard tissue destruction, 
dental mobility, and the loss of dental elements [4,5]. The inflamed 
periodontal tissue may serve as a chronic source of bacteria, bacterial 
products and may trigger the release of inflammatory mediators such 
as tumor necrosis factor-α (TNF-α), interleukin (IL) 6 and 1 which have 
important effects on lipid and glucose metabolism [6]. DM is a metabolic 
disorder characterized by hyperglycemia resulting from a defective 
insulin secretion and/or activity. Periodontitis is an inflammatory 
response to a bacterial challenge and represents a portal of entry for 
periodontal pathogens, bacterial endotoxins, and proinflammatory 
cytokines [7]. Inflammation is a central feature of the pathogenesis 
of diabetes and periodontitis. TNF-α and IL-6 are the main inducers 
of acute-phase proteins, including C-reactive protein (CRP), and both 
have been shown to impair intracellular insulin signaling, potentially 
contributing to insulin resistance [8]. The link between diabetes and 
periodontitis is bidirectional. Diabetes has well been established as 
a major risk factor for periodontitis and direct relationships have 
been demonstrated between degree of hyperglycemia and severity of 
periodontitis. Similarly, mechanisms underlying the effect of periodontal 
inflammation on blood glucose level have also been proven [9]. The 
presence of periodontal diseases can have a significant impact on the 
metabolic state in diabetes. Periodontitis is also associated with an 
increased risk for diabetic complications. Studies have shown that 
diabetic patients with periodontal infection have a greater risk of 
worsening glycemic control over time compared to diabetic subjects 
without periodontitis [10]. Thus, the local oral inflammatory disease, 
periodontitis, may induce and perpetuate a systemic inflammation 
that may aggravate systemic diseases such as cardiovascular disease, 
pulmonary disease, rheumatoid arthritis, and diabetes mellitus [7]. 
Periodontal treatment that reduces gingival inflammation aids in 
the control of hyperglycemia. Antibiotics are important adjuncts in 
the treatment of infectious diseases, including periodontitis [11]. 
Among the various antibiotics, azithromycin, and metronidazole are 
selected for the study. Azithromycin is a macrolide, broad spectrum 
antibiotic whose concentration in gingival crevicular fluid (GCF) 
is higher than that of serum and also exerts post antibiotic effect. In 
addition, azithromycin is preferentially taken up by phagocytes, and 
hence, its level in infected tissues is much higher than in similar non-
infected sites. Azithromycin has been used for the treatment of chronic 
periodontitis [12-14]. Metronidazole is a nitroimidazole bactericidal 
antibiotic and effective against anaerobes. Oral metronidazole is widely 
used in chronic periodontitis treatment due to its anti-anaerobic 
effect [15]. Metronidazole can readily attain effective anti-bacterial 
concentrations in gingival tissue and crevicular fluid [16]. Hence, 
this study is designed to assess the effect of periodontal therapy 
on glycated hemoglobin (HbA1c) in patients with type 2 diabetes 
mellitus by treating the chronic periodontitis using azithromycin and 
metronidazole following scaling and root planning (SRP).
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METHODS
The study entitled “effect of azithromycin and metronidazole for chronic 
periodontitis on glycemic control in type II diabetes” was conducted as 
a prospective observational study in the dental department of Tertiary 
Care Hospital for 9 months. The study protocol was approved by the 
institutional ethics committee of Vels University (Approval no: IEC/
DOPI/2015/21). The schedule for patient follow-up and treatment plan 
is shown in Table 1.
Consent from hospital authority
The protocol of the proposed study was submitted as printed copies 
to the medical superintendent and dentists for review and approval. 
Guidance of the senior dentist available was extended on request from 
the scholar. Consent from the hospital authorities and dentists were 
obtained before accessing the data from the patients. Clinical and 
biochemistry data of the patients who fulfilled the inclusion criterion 
were documented from the case sheets and recorded in a separately 
designed case report form.
Study design
The study comprised three groups and each group included 30 patients 
as follows:
• Group I: 30 patients treated with SRP and azithromycin (500 mg OD 
× 3 days)
• Group II: 30 patients treated with SRP and metronidazole (250 mg 
TDS × 5 days)
• Group III: 30 patients treated with SRP.
SRP was done using ultrasonic scaler and Gracey’s curettes.
Patient recruitment
Detailed information regarding disease condition, treatment plan, 
and oral hygiene instructions were provided to the patients willing to 
participate in the study. Written informed consents were obtained after 
explaining the study protocol to each individual patient.
Inclusion criteria
Patients of both gender between 35 and 70 years of age with 
uncontrolled type II DM and chronic periodontitis that has a probing 
depth of 4 mm - 7 mm in at least 3 sites were included in the study.
Exclusion criteria
Patients on regular anti-inflammatory medications, who have taken 
systemic antibiotics within the last 3 months before enrollment, 
patients with significant history of smoking, tobacco use, alcoholism and 
drug abuse, pregnant and lactating women, patients who have received 
periodontal therapy within the last 6 months, patients with less than 
8 natural teeth in oral cavity and poor dental prognosis, patients who 
are allergic to azithromycin and metronidazole and patients with major 
medical complications were excluded from the study.
Clinical parameters
1. Gingival index - Loe and Silness [17].
2. Plaque index - Loe and Silness [17].
3. Pocket probing depth was recorded to nearest millimeter using UNC 
15 probe [18].
4. Clinical attachment levels in millimeter from reference point 
(cemento enamel junction) to the base of pocket using customized 
occlusal acrylic stents and UNC 15 probe [18].
5. HbA1c, serum CRP and lipid profile - collected from case sheets.
Statistical analysis
Comparison between three groups was analyzed by means of one-
way analysis of variance (ANOVA) and student t-test to determine the 
presence or absence of statistically significant difference wherever 
necessary. Wherever computed, the value of p<0.05 was considered 
statistically significant, since the confidence interval was maintained 
at 95%. Univariate analyses were carried out by Pearson’s correlation. 
Predictors of reduction in HbA1c level was determined by multiple 
linear regression analysis. All statistical analyses were performed 




A total of 90 patients who fulfilled the inclusion criteria were enrolled in 
the study. The demographic and clinical characteristics of the patients 
included in the study are shown in Tables 2 and 3.
The mean±standard deviation (SD_ age of the studied population was 
found to be 51.2 (7.51) years with a median age of 52 years. 52 (57.7%) 
patients were male, whereas 38 (42.2%) patients were female. 
Statistically significant difference was not observed between mean±SD 
age of males (50.92 [8.01]) and females (51.57 [6.74]) (p=0.6865).
Statistically significant difference in the above parameters was not 
found between genders (unpaired t-test).
Effect of oral azithromycin and metronidazole on HbA1c level
The presence of statistically significant difference in HbA1c between 
baseline and third month was (intra group comparison) determined 
by means of student t-test, whereas one-way ANOVA was used to 
determine inter group difference. A mean decrease in HbA1c level was 
observed during the 3rd month. Inter group comparison through one 
way ANOVA showed periodontitis treatment with oral azithromycin 
as an adjunct to SRP to be more effective on glycemic control when 
compared to the other two groups as shown in Table 4. Changes in 
HbA1c levels after 3 months of periodontal therapy was found to be 
significantly high in azithromycin treated group than metronidazole 
treated group as shown in Fig. 1.
Determination of factors influencing change in HbA1c (ΔHbA1c): 
Effect of periodontal therapy
Logistic linear regression analysis was carried out to determine 
factors that cause change in HbA1c levels. Expected explanatory 
variables were regressed against the dependent variable, ΔHbA1c. 
Concomitant insulin therapy, change in CRP, life style modification and 
periodontal therapy were found to be significant covariates affecting 
ΔHbA1c. Thus, periodontal therapy was found to be a significant 
factor in achieving glycemic control in type II diabetes patients with 
chronic periodontitis. The results of the regression analysis are shown 
in Table 5a and b.
Effect of oral azithromycin and metronidazole on dental 
parameters
Gingival index, plaque index, probing depth, and clinical attachment 
loss were observed to be significantly decreased after periodontal 
therapy in chronic periodontitis patients. Oral azithromycin therapy 
as an adjunct to SRP was found to be comparatively more effective in 
treating chronic periodontitis than oral metronidazole and SRP alone 
groups as shown in Tables 6-9.
Table 1: Review schedule
Review Group I (30 patients) Group II (30 patients) Group III (30 patients)
R0 (baseline) Before periodontitis treatment Before periodontitis treatment Before periodontitis treatment
R1 (1 month) SRP+azithromycin SRP+metronidazole SRP
R2 (3 months) SRP+azithromycin SRP+metronidazole SRP
R0=Baseline review, R1=Review 1, R2=Review 2, OHI: Oral hygiene instructions, SRP: Scaling and root planning
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whereas systemic antibiotic therapy comprises the use of antibiotics 
such as amoxicillin, macrolides, clindamycin, fluoroquinolones, 
cephalosporins, and metronidazole [20]. In the current study, 
effectiveness of azithromycin and metronidazole has been 
comparatively evaluated. Longer half-life (t1/2) of azithromycin aids 
increased dosing interval and decreased the course of treatment. 
Further azithromycin exerts post antibiotic effect conferring longer 
protection to oral cavity [21]. On the other hand, metronidazole is 
widely used in periodontal therapy since organisms associated with 
periodontal infection are often gram negative anaerobes. In the 
current study, the effectiveness of azithromycin and metronidazole 
was comparatively assessed in uncontrolled diabetic patients 
who underwent scaling and root planning. Patients who received 
azithromycin showed statistically significant reduction in gingival 
index, plaque index, pocket probing depth, and clinical attachment 
loss at first and third month post therapy. The decrease in intensity 
of periodontal infection was comparatively higher in patients who 
received azithromycin than in patients who received metronidazole 
and SRP alone as shown in Tables 6-9. As discussed earlier, the 
potential efficacy of azithromycin could be attributed to its ability to 
attain higher concentrations in the GCF making it an ideal treatment 
choice for chronic periodontitis [22].
Chronic periodontitis has negative impact on glycemic control. Local 
production of cytokines in the periodontal tissue affects glycemic 
control through systemic exposure and impairing intracellular 
insulin signaling thus potentially contributing to insulin 
resistance [23]. Hyperglycemic state may thus be enhanced in 
chronic periodontitis patients and periodontal therapy can therefore 
result in reduced HbA1c [24]. In this study, patients who received 
azithromycin showed comparatively higher reduction in HbA1c than 
patients who received metronidazole and SRP alone. The mean±SD 
reduction in HbA1c after 3 months was 2.18 (1.46) for azithromycin 
treated patients, whereas it was 1.09 (0.46) and 0.14 (0.24) for 
metronidazole and SRP alone group, respectively. Statistically 
significant difference in mean HbA1c reduction was found between 
Table 2: Age‑wise distribution
Age 
range
Number of patients (%) 
n=90
Mean±SD Age quartile
31-40 9 (10) 37.88±1.52 35-40
41-50 31 (34.4) 46.03±2.45 41-50
51-60 40 (44.4) 55.17±2.59 51-60
61-70 10 (11.11) 63.4±1.49 62-66
SD: Standard deviation
Table 3: Clinical and periodontal characteristics of studied 
patients
Parameter Mean±SD Median Range p
BMI (kg/m2) 29.6±2.52 29 19.4-36.5 0.096
Plaque index 2.32±0.44 2.4 1.2-3 0.5207
Gingival index 2.15±0.46 2.35 1.2-2.8 0.9380
PPD (mm) 5.32±0.92 5 8-15 0.1901
CAL (mm) 11.01±1.78 11 8-15 0.1070
HbA1c (%) 11.36±1.47 11.35 8.8-14.8 0.3659
BMI: Body mass index, SD: Standard deviation, HbA1c: Glycated hemoglobin
Table 4: Comparison of baseline and post‑treatment HbA1c level
Group HbA1c
Baseline 3 months p*
I (n=30) 11.46±1.57 9.28±0.81 0.000
II (n=30) 11.38±1.47 10.47±1.45 0.000
III (n=30) 11.25±1.38 11.20±1.34 0.033
p** 0.352 0.0332
*p value retrieved by paired student t-test, **p value retrieved by one-way 
ANOVA, HbA1c: Glycated hemoglobin, ANOVA: Analysis of variance
Table 5a: Model summary
Model R R2 Adjusted R2 Standard error of the 
estimate
1 0.768a 0.590 0.585 0.79279
2 0.826b 0.682 0.675 0.70157
3 0.839c 0.704 0.694 0.68068
4 0.855d 0.731 0.718 0.65369
aPredictors: (Constant), insulin therapy, bPredictors: (Constant), insulin therapy, 
change in CRP, cPredictors: (Constant), insulin therapy, change in CRP, life style 
modification, dPredictors: (Constant), insulin therapy, change in CRP, life style 
modification, periodontal treatment, CRP: C- reactive protein, CRP: C-reactive 
protein
Table 5b: Coefficients
Model Unstandardized coefficients Standardized coefficients t Significant
Beta Standard error Beta
4
(Constant) −0.379 0.206 −1.835 0.070
Insulin therapy 1.023 0.221 0.379 4.637 0.000
Change in CRP 1.233 0.413 0.264 2.988 0.004
Lifestyle 0.627 0.217 0.186 2.892 0.005
Periodontal treatment 0.358 0.125 0.227 2.872 0.005
Dependent variable: Change in HbA1c, CRP: C-reactive protein, HbA1c: Glycated hemoglobin
Fig. 1: Effect of oral antibiotic therapy on HbA1c level
DISCUSSION
The effect of periodontal inflammation on systemic and metabolic 
diseases has been well established. The current therapeutic regimens 
for periodontitis include the use of local and systemic antibiotics 
with scaling, root planning, and oral hygiene practices [19]. Local 
antibiotics used are tetracycline fibers, minocycline gel, etc. 
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patients who received concomitant antibiotic therapy and patients 
who received SRP alone as shown in Fig. 1. Similarly, the incidence 
of diabetic control was found to be high in azithromycin treated 
patients suggestive of a potential role of azithromycin in glycemic 
control as shown in Fig. 2.
Fig. 2: Incidence of glycemic control between treatment groups. 
Statistically significant difference in incidence of diabetic control 
was found between azithromycin, metronidazole and scaling and 
root planning alone groups (p=0.0306)
Table 6: Comparison of baseline and post‑treatment gingival 
index
Group Gingival index
Baseline 1 month 3 months p
I (n=30) 2.20±0.49 1.51±0.47 1.29±0.46
II (n=30) 2.10±0.43 1.77±0.44 1.52±0.41 0
III (n=30) 2.16±0.48 1.95±0.45 1.65±0.46 0.001
p 0.72 0.013 0.047 0
Table 7: Comparison of baseline and post‑treatment plaque 
index
Group Plaque index
Baseline 1 month 3 months p
I (n=30) 2.38±0.45 1.54±0.33 1.30±0.32 0.000
II (n=30) 2.30±0.44 1.83±0.41 1.48±0.36 0.000
III (n=30) 2.28±0.43 1.96±0.44 1.58±0.41 0.000
p 0.648 0.000 0.013
Table 8: Comparison of baseline and post‑treatment pocket 
probing depth
Group Probing depth
Baseline 1 month 3 months p
I (n=30) 5.43±0.99 4.63±0.80 4.13±0.50 0.000
II (n=30) 5.23±0.92 4.70±0.74 4.40±0.55 0.000
III (n=30) 5.30±0.86 5.03±0.66 4.80±0.60 0.033
p 0.704 0.089 0.075
Table 9: Comparison of baseline and post‑treatment clinical 
attachment loss
Group Clinical attachment loss
Baseline 1 month 3 months p
I (n=30) 11.07±2.00 9.07±1.95 8.33±1.87 0.000
II (n=30) 11.00±1.81 9.90±1.35 9.07±1.39 0.000
III (n=30) 10.97±1.52 10.30±1.16 9.53±1.09 0.000
p 0.976 0.009 0.010
CONCLUSION
Periodontal therapy with oral azithromycin has effectively reduced 
HbA1c. Hence, periodontal therapy with oral azithromycin can be 
employed as a supportive strategy for management of diabetes 
mellitus. Henceforth, prevention and control of periodontal disease 
along with antibiotics must be considered an integral part of glycemic 
control. However, due to the lesser sample size in this study, further 
investigations are required to confirm the effect of periodontal therapy 
on systemic diseases.
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